Lisata Therapeutics Inc

Research Lisata Therapeutics Inc (LSTA) on Bullrun: market cap USD 15.87M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 15.87M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 170.00K-USD 16.59M-USD 15.98Mn/a-1.91USD 15.96MUSD 0USD 14.86M
FY2024USD 1.00M-USD 19.99M-USD 19.36Mn/a-2.4USD 16.21MUSD 137.00KUSD 29.57M
FY2023USD 0-USD 20.84M-USD 20.03Mn/a-2.58USD 22.59MUSD 168.00KUSD 48.15M
FY2022USD 0-USD 54.23M-USD 21.46Mn/a-10.47USD 32.15MUSD 561.00KUSD 66.58M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 15.87Mn/an/an/a
20252025-12-31USD 16.43Mn/an/an/a
20242024-12-31USD 25.06Mn/an/an/a
20232023-12-29USD 22.22Mn/an/an/a
20222022-12-30USD 19.89Mn/an/an/a
20212021-12-31USD 50.22Mn/an/an/a

About Lisata Therapeutics Inc

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Lisata Therapeutics Inc's market cap?

Lisata Therapeutics Inc's market capitalization is USD 15.87M.

What does Lisata Therapeutics Inc do?

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc.